We have examined the effects of transforming growth factor-beta (TGFb) signaling on mammary epithelial cell survival. Transgenic mice expressing an active mutant of Alk5 in the mammary gland (MMTV-Alk5
Introduction
The transforming growth factor-betas (TGFbs) are members of a large superfamily of pleiotropic cytokines that also includes the activins and the bone morphogenetic proteins (BMPs). Members of the TGFb family regulate complex physiological processes such as cell proliferation, differentiation, adhesion, cell-cell and cell-matrix interactions, motility, and cell death, among others (Massague, 1998) . Dysregulation of TGFb signaling contributes to several pathological processes including cancer, fibrosis, and autoimmune disorders (Massague et al., 2000) . The TGFbs elicit their biological effects by binding to type II and type I transmembrane receptor serine-threonine kinases (TbRII and TbRI) which, in turn, phosphoylate Smad2 and 3. Phosphorylated Smad2/3 associate with Smad4 and, as a heteromeric complex, translocate to the nucleus, where they regulate gene transcription. The inhibitory Smad7 downregulates TGFb signaling by binding to activated TbRI and interfering with its ability to phosphorylate Smad2/3 (Derynck and Zhang, 2003; Shi and Massague, 2003) .
TGFb signaling is regulated in part by Smad proteolysis. TGFb receptor-mediated activation results in multiubiquitination of Smad2 in the nucleus and subsequent degradation of Smad2 by the proteasome (Lo and Massague, 1999) . Activation of TGFb receptors also induces mobilization of a Smad7-Smurf complex from the nucleus to the cytoplasm; this complex recognizes the activated receptors and mediates their ubiquitination and internalization via caveolin-rich vesicles, leading to termination of TGFb signaling (Di Guglielmo et al., 2003) . Other signal transducers/pathways have been implicated in TGFb actions. These include the extracellular signal-regulated kinase (Erk), c-Jun N-terminal kinase (Jnk), p38 mitogen-activated protein kinase (MAPK), protein phosphatase PP2A, phosphatidylinositol-3 kinase (PI3K), and the family of Rho GTPases (reviewed in Derynck and Zhang, 2003) . Although signaling by Smads has been shown to be causally associated with the antiproliferative effect of TGFb (Liu et al., 1997; Datto et al., 1999) , the role of non-Smad effectors on mediating the cellular effects of TGFb is less well characterized.
TGFb can behave as both a tumor suppressor and a tumor promoter. Its tumor suppressor role can be explained by its ability to inhibit mitogenesis (Alexandrow and Moses, 1995) , induce apoptosis , maintain tissue architecture (Engle et al., 1999) , inhibit genomic instability (Glick et al., 1996) , and induce replicative senescence (Kordon et al., 1995; Boulanger et al., 2005) . Consistent with its antiproliferative effect, overexpression of active TGFb1 or TbRI in the mammary gland of transgenic mice delays gland ductal extension and alveolar development (Jhappan et al., 1993; Pierce et al., 1993; and protects from oncogene-or carcinogeninduced transformation (Pierce et al., 1995) . Expression of dominant-negative TbRII in the mouse mammary gland results in enhanced propensity for carcinogeninduced and spontaneous mammary cancers (Bottinger et al., 1997; Gorska et al., 2003) . Overexpression of TGFb3 in the alveolar epithelium of lactating mice causes alveolar cell apoptosis, whereas Smad3-null mammary epithelium exhibits impaired postlactational involution and cell death (Nguyen and Pollard, 2000; Yang et al., 2002) , further consistent with the tumorsuppressive role of TGFb.
Other data, however, suggest that TGFb can also act as a survival factor in normal mammary epithelium. During pregnancy, there is a three-fold increase in apoptosis in ductal and alveolar cells from Tgfb1 heterozygote compared to wild-type (WT) mouse mammary glands (Ewan et al., 2002) . Postpubertal mice in which Tgfbr2 was conditionally deleted in the mammary gland also exhibit a much higher rate of apoptosis compared to controls (Forrester et al., 2005) . Reports using cancer cells and/or transgenic mammary tumors further support a role for TGFb in the suppression of apoptosis (Huang et al., 2000; Muraoka et al., 2003) . Conditional overexpression of active TGFb1 in a triple transgenic model expressing polyomavirus middle T antigen in the mammary gland (MMTV/PyVmT) inhibits apoptosis and accelerates metastases (Muraoka-Cook et al., 2004) . In MMTV/ PyVmT transgenic mice, systemic administration of a soluble TbRII increases tumor cell apoptosis and reduces metastases (Muraoka et al., 2002a) . In transformed cells, treatment with TGFb enhances survival via Akt-induced phosphorylation of FKHRL1 (Shin et al., 2001) . TGFb has been shown to activate PI3K and its target Akt (Higaki and Shimokado, 1999; Bakin et al., 2000; Yi et al., 2005) . Although the signaling programs regulating TGFb-mediated protection from cell death are not completely understood, this protection is blocked by the PI3K inhibitor LY294002 and/or expression of dominantnegative Akt (Shin et al., 2001; Horowitz et al., 2004; Muraoka-Cook et al., 2004) . These data are consistent with the ability of TGFb to behave as a tumor promoter in late phases of transformation (Wakefield and Roberts, 2002) .
To further examine the role of active TGFb signaling in mammary epithelial cell survival in vivo, we generated transgenic mice expressing a mutant type I receptor (Alk5) containing a substitution of threonine 204 with aspartic acid (Alk5  T204D ) , which results in constitutive activation of the receptor kinase in the absence of added ligand (Wieser et al., 1995) . Expression of mutant Alk5 TD was directed to the mammary epithelium using the mouse mammary tumor virus (MMTV) promoter. Although ductal extension was delayed during mammary gland morphogenesis, apoptosis was markedly reduced in pubertal terminal endbuds (TEBs) and during postlactational involution. Primary mammary epithelial cells (PMECs) from transgenic glands contained reduced levels of Smad2/3/4 and higher levels of c-myc compared to WT cells, and were insensitive to TGFb-induced antimitogenesis. They also exhibited high levels of ligand-independent PI3K and Akt activity, as well as enhanced survival and adhesion. Treatment with an Alk5 kinase inhibitor upregulated Smad2/3 levels, reduced PI3K activity, and P-Akt, and inhibited cell survival, suggesting a causal relation between Alk5 TD and the observed phenotypic changes. Finally, although Alk5 TD -expressing mice did not develop mammary tumors, bigenic MMTV-Alk TD Â Neu mice developed tumors that were more metastatic than those occurring in MMTV-Neu mice. These data suggest that dysregulated TGFb signaling can confer PI3K-dependent enhanced survival to nontransformed mammary epithelial cells and accelerate metastatic progression of oncogene-induced cancers.
Results
Activated Alk5 reduces apoptosis and increases periductal fibrosis in the mammary gland We generated two transgenic mouse lines expressing a cDNA construct encoding mutant Alk5 T204D ( Figure 1a ). The Alk5 construct was tagged with a hemaglutinin (HA) epitope at its carboxy-terminus. Expression of Alk5 TD was directed to mammary epithelium using the MMTV promoter. In all, 11 founders were tested by PCR using primers P1 and P2 from the MMTV sequence (data not shown); three animals were identified as having genomic transgene (Tg) insertion, two of which (lines 4 and 11) were able to transmit the Tg to their offspring. Expression of the HA-tagged Alk5 TD in the mammary glands of 12-week-old virgin females from both transgenic lines was confirmed by Alk5 immunoblot of HA precipitates from mammary gland extracts (Figure 1c ). Multiple tissues were screened for Tg expression by HA and Alk5 Western analysis. Expression of HA-tagged Alk5 was limited to the mammary tissues from both transgenic lines. Although Alk5 expression was detected in kidney, thymus, heart, and liver extracts, this expression was from the endogenous but not the HA-tagged Alk5 protein (Figure 1d ). Using immunofluorescence with HA and Alk5 antibodies, both HA and Alk5 expression were detected in the mammary epithelium of MMTV-Alk5 TD mice, but not in WT mice (Figure 1e ). HA and Alk5 expression was diffuse in mammary epithelium, suggesting homogenous expression of the Tg.
Overexpression of active TGFb1 in the mammary gland of transgenic mice has been shown to delay ductal extension and alveolar development. Similar to MMTVTGFb1 S223/225 mice, mammary whole mounts from pubertal MMTV-Alk5 TD mice showed that ductal extension into the mammary fat pad was initially delayed compared to age-matched WT siblings (Figure 2a) . However, by 20 weeks of age, the ductal tree had completely permeated the mammary fat pad in MMTV-Alk5 TD mice. This delay in ductal outgrowth may have been due to a decrease in cellular proliferation within the highly mitotic TEBs at the distal ends of the developing ductal tree. However, proliferation measured by the proportion of cells in the TEBs from 7-week-old mice that stained positive for proliferating cell nuclear antigen (PCNA) was similar in WT and transgenic mice (22.472.3 vs 21.674.5, respectively; n ¼ 8 per group) (Figure 2b ) The TEBs also exhibit high levels of apoptosis, which contributes to the canalization of the ductal network. At mid-puberty (7 weeks), TEBs from
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TD glands displayed a >3-fold reduction in TUNEL þ cells compared to TEBs from age-matched WT siblings. Despite the reduced rate of cell death, canalization of the ductal tree was not impaired in MMTV-Alk5 TD mice (Figure 2c ). Histological analysis of 20-week-old transgenic glands at 20 weeks of age showed abundant periductal eosinophilic staining, which was not present in age- matched WT siblings or in MMTV-TGFb1 S223/225 mice ( Figure 3a) . Since TGFb signaling results in secretion of ECM proteins, we speculated that active Alk5 signaling would enhance the secretion of ECM components.
Masson's trichrome staining revealed increased collagen deposition surrounding the transgenic ducts compared to WT (Figure 3b ). DAPI (nuclear) staining revealed enhanced cellularity outside the ductal layer. Using immunohistochemistry (IHC) for smooth muscle actin (SMA), a marker of myoepithelial cells, only a singlecell layer of myoepithelium was detected in direct apposition to the ductal epithelium ( Figure 3c ). This suggested the presence of other cells such as fibroblasts within the periductal collagen. Staining with antibodies against active TGFb1 showed an excess of active ligand throughout the periductal space (Figure 3d ), suggesting the possibility that TGFb-stimulated resident fibroblasts could be synthesizing the excessive periductal collagen.
To examine the effect of Alk5 TD on mammary development during pregnancy, we examined pregnant mammary glands at 16.5 days post-coitum (d.p.c). Both WT and transgenic mammary glands exhibited abundant lobuloalveolar structures filled with proteinacious secretions. However, epithelial content was less and adipose tissue more abundant in glands from MMTVAlk5 TD compared to WT mice ( The reduced apoptosis in MMTV-Alk5 TD TEBs suggested the possibility of reduced programmed cell death during postlactational involution and architectural remodeling of the mammary gland, another physiological state of the gland during which epithelial apoptosis is high. Involution of the gland was induced after 10 days of lactation by withdrawing pups from nursing mothers. Gland whole mounts and histology were examined at 1, 3, 5, 7, and 21 days post-forced wean (d.p.f.w), revealing a delay in the elimination of TD glands was decreased three-fold compared to WT glands at 3 d.p.f.w., but both were approximately equal at 7 d.p.f.w. (Figure 5d ). These results suggest that active Alk5 was inducing survival signals that antagonized epithelial apoptosis during postlactational involution.
Activated Alk5 downregulates expression of Smads and induces PI3K/Akt signaling
To determine the possible mechanisms by which Alk5 TD expression modulates cell survival, we examined protein levels of molecules that mediate TGFb signaling in whole mammary gland lysates from 12-week-old virgin mice. By immunoblot analysis, Smad2, Smad3, and Smad4 levels were decreased in MMTV-Alk5 TD compared to WT glands, while levels of the inhibitory Smad7 were elevated ( Figure 6a ). The reduced Smad2 content in transgenic glands was confirmed by immunofluorescence ( Figure 6b) . However, the steadystate Smad2 RNA levels were approximately similar between both types (Figure 6c ). Treatment with TGFb of mammary cells harvested from WT glands markedly induced Smad2 phosphorylation within 30 min and inhibited their proliferation. These effects were not observed in PMECs from transgenic glands (Figure 6d ). In addition, c-myc was elevated in MMTV-Alk5 TD mammary glands as well as Ser473-phosphorylated (active) Akt without a change in total Akt protein levels. Treatment with TGFb eliminated detectable cmyc levels in WT, but not in the transgenic cells (data not shown). Levels of b-tubulin and p21
Cip1 were similar in glands of both genotypes (Figure 6a ). Since TGFb can activate PI3K and its target kinase Akt (above), we examined PI3K catalytic activity. The regulatory subunit of PI3K, p85, was precipitated from PMECs; p85-containing immune complexes were tested for their ability to stimulate formation of 3 0 phosphorylated inositol lipids in vitro. MMTV-Alk5 TD cells exhibited a markedly higher levels of ligand-independent, p85-associated PI3K activity compared to WT (Figure 6e ).
We next examined if forced expression of Smads, which were downregulated in Tg-expressing cells, would restore Alk5-mediated Smad2 phosphorylation and antiproliferative action. Therefore, we transduced the Alk5 TD -PMECs with adenoviruses encoding FLAGtagged Smad2 and Smad4. Immunoblots of Ad. Smad2-transduced cell lysates suggested that the ectopic Smad2 was not expressed in MMTV-Alk5 TD cells (Figure 7a ), even though expression of b-galactosidase was widely detected in cells transduced with an Ad.lacZ control (Figure 7b ). This result plus the maintained levels of Smad2 RNA (Figure 6c ) suggested a posttranscriptional mechanism for Alk5-mediated downregulation of Smad2 protein levels.
Receptor-mediated activation of Smad2 has been shown to result in ubiquitination and subsequent degradation of Smad2 in the proteasome (Lo and Massague, 1999) . Thus, we examined if treatment of MMTV-Alk5 TD PMECs with the proteasome inhibitor PS-341 (Adams, 2004) would restore Smad2 protein levels and function. Treatment with PS-341 for 24 h restored Smad2 expression and detectable -Smad2 P-Smad2 levels in cells transduced or not with Ad.Smad2 (Figure 7c ). In addition, treatment with PS-341 downregulated the enhanced basal levels of c-myc observed in the Alk5 TD -expressing cells. Furthermore, ligand-independent transcriptional activity in MMTV-Alk5 TD PMECs transiently transfected with a reporter construct containing 12 Smad-binding elements in tandem, p(CAGA) 12 -Lux, was enhanced 17-fold by PS-341 alone. Proteasome inhibition did not increase p(CAGA) 12 -Lux expression in WT cells although it modestly enhanced ligand-induced reporter activity (Figure 7d ). Finally, proteasome inhibition restored the ability of exogenous TGFb to inhibit cell cycle progression of Alk5 TD -expressing cells. Tg-expressing cells proliferated faster than WT PMECs with a doubling time of 28 vs 38 h and a basal S phase of 15 vs 11% when grown in monolayer (not shown). In the absence of PS-341, TGFb did not increase the G1 phase, or reduced the S-phase fraction in Alk5 TD cells. However, addition of PS-341 alone to Alk5 TD cells increased the G1 fraction from 72 to 91% and reduced S phase from 15 to 6% after 24 h (Figure 7e ).
Alk5 kinase inhibitor downregulates PI3K in MMTV-Alk5
TD mammary cells To determine if active Alk5 was causally associated with the enhanced PI3K activity in Tg-expressing cells, we utilized the Alk5 kinase small-molecule inhibitor LY580276. LY580276 is a para-fluorophenyl-substituted dihydropyrrolopyrazole that is highly selective for Alk5 (IC 50 0.18 mM, K i 37 nM) relative to TbRII (IC 50 >20 mM), p38a (IC 50 >20 mM), and a panel of 39 additional kinases with an IC 50 >10 mM. It inhibits TGFb-stimulated p3TP-Lux reporter activity in Mink lung cells (IC 50 96 nM) and NIH3T3 proliferation (IC 50 39 nM) (Peng et al., 2005) . The crystal structure of LY580276 in Alk5 T204D has been solved, which confirms binding at the receptor's ATP site (Sawyer et al., 2004) . In a dose-dependent fashion, treatment with the Alk5 inhibitor for 24 h restored Smad2 levels while reducing basal P-Smad2, P-Akt, and c-myc in MMTV-Alk5 TD cells. In addition, preincubation for 1 h with 2-10 mM LY580276 blocked both basal and ligandinduced P-Smad2 and P-Akt in a dose-dependent manner (Figure 8a ). Treatment with LY580276 also inhibited p85-associated PI3K activity in MMTVAlk5 TD cells. A similar level of inhibition was seen with LY294002, a small molecule that directly inhibits p110, the catalytic subunit of PI3K (Figure 8b) . Finally, treatment with LY294002 or LY580276 resulted in a >2-fold increase in apoptosis in Tg-expressing PMECs (Figure 8c ), suggesting that Alk5 TD and PI3K were causally associated with the increased epithelial cell survival.
Activated Alk5 accelerates oncogene-induced mammary tumor progression Despite the prosurvival effect of the Alk5 Tg product, we have not observed mammary hyperplasias or cancers in MMTV/Alk5 TD of >2 years of age. Recently, overexpression of active TGFb1 or an active mutant of TbRI containing T204D and L193A/P194A (to prevent binding of the FKBP-12 inhibitor) has been shown to increase extravascular metastases in bigenic mice also expressing c-Neu or mutant Neu, respectively (Muraoka et al., 2003; . Therefore, we crossbred MMTV-Alk5 TD with MMTV/Neu mice. Whole mounts of mammary glands from 7-week-old MMTV/Neu mice showed the previously described precocious alveolar budding and branching of primary ducts. In glands from age-matched bigenic mice, Alk5 TD failed to delay ductal extension but appeared to accelerate ductal branching (Figure 9a ).
Neu and Alk5 TD Â Neu mice were examined weekly to detect the presence of mammary tumors. Tumor latency was similar in both genotypes (251 vs 269 days, respectively), with 100% of mice of either genotype PMECs from WT and MMTV-Alk5 TD mice were treated or not with 2 ng/ml TGFb1 for 1 h and lysed. Cell lysates were precipitated with p85 antibodies and immune complexes tested for their ability to generate phosphorylated inositides in vitro as indicated in Materials and methods. PIP, PIP2, and PIP3 are identified by the arrows. Where indicated, the PI3K inhibitor Wortmannin (Wn; 500 nM) was added to the kinase reaction in vitro as a positive control. To correct for the amount of precipitated PI3K, p85 precipitates were subjected to immunoblotting with a p85 antibody (bottom). (Figure 9d ), consistent with high expression of the Tg product. Although levels of TbRIII were lower in the bigenic cells and those expressing Alk5 TD alone compared to MMTV-Neu PMECs, the content of type II receptor protein was not appreciably different in cells expressing Alk5 TD .
Discussion
We have examined the biochemical and cellular effects of aberrant TGFb signaling in mammary epithelium by overexpressing a constitutively active mutant of Alk5 in the mouse mammary gland. Expression of Alk5 T204D in mammary epithelial cells resulted in delayed ductal extension during gland morphogenesis, as well as reduced apoptosis in TEBs and involuting mammary glands. The last two are physiological states of the gland during which the rate of cell death is high. PMECs isolated from transgenic glands exhibited a markedly lower content of Smad2/3 protein compared to controls, high constitutive PI3K and Akt activities, and were insensitive to TGFb-mediated growth arrest ( Figure 6 ) and Smad transcriptional reporter activity (Figure 7) . Treatment of the transgenic mammary cells with a proteasome inhibitor increased steady-state Smad2/3 protein levels and ligand-independent Smad transcriptional reporter activity, as well as reduced both c-myc protein and basal cell proliferation in the absence of exogenous TGFb (Figure 7) . These results suggest that Alk5 activity increased Smad proteolysis, consistent with the observation that TGFb receptor activation results in ubiquitination and proteasome-mediated degradation of Smad2 (Lo and Massague, 1999) .
c-myc levels were higher in Alk5 TD -expressing cells compared to controls, and they were unresponsive to added TGFb. The downregulation of c-myc is required for the antimitogenic action of TGFb in order to deprive the cell of growth-promoting functions and facilitate the induction of the Cdk inhibitors p15 INK4B and p21 CIP1 (Alexandrow and Moses, 1995; Chen et al., 2001) . Smad3 is required as part of a complex that mediates TGFb-induced downregulation of c-myc (Chen et al., 2002) . Treatment with the proteasome inhibitor PS-341 upregulated Smad3, restored Alk5-induced transcriptional activity, downregulated c-myc, and induced cell cycle arrest in the Alk5 TD -expressing cells. Therefore, we speculate that the low Smad3 levels contributed to derepression (and a higher level) of c-myc in the transgenic cells, further antagonizing the antiproliferative effect to TGFb.
In this study, overexpression of active Alk5 resulted in high levels of constitutive PI3K activity in mammary epithelial cells. PI3K increases the formation of intracellular 3 0 phosphoinositol lipids, signal transducers involved in the regulation of cell cycle progression, glucose metabolism, cell motility, EMT, and inhibition of apoptosis (Vivanco and Sawyers, 2002) . TGFb stimulates PI3K activity as well as phosphorylation and activation of the PI3K-dependent Akt serine-threonine kinase (Higaki and Shimokado, 1999; Bakin et al., 2000) . Both TbRII and Alk5 have been shown to associate indirectly with p85. Although the association of p85 with TbRII is constitutive, the Alk5-p85 interaction is ligand-dependent (Yi et al., 2005) . TGFb-mediated cell motility and protection from apoptosis are blocked by LY294002 and/or expression of dominant-negative Akt (Bakin et al., 2000; Shin et al., 2001; Horowitz et al., 2004; Muraoka-Cook et al., 2004) . Inhibition of PI3K has also been shown to reverse the fibroblastoid phenotype of TGFb-treated Rastransformed hepatocytes to an epithelial phenotype (Gotzmann et al., 2002) , further suggesting that PI3K is an effector of the transforming effects of TGFb. By repressing the induction of p21 CIP1 , activation of the PI3K/Akt pathway can inhibit the cytostatic effect of TGFb (Seoane et al., 2004) . In addition, phosphorylated Akt can sequester Smad3 and prevent its phosphorylation, association with Smad4, and nuclear translocation, hence blocking TGFb-induced apoptosis (Conery et al., 2004; Remy et al., 2004) .
Consistent with the prosurvival effect of the PI3K pathway in mammary epithelium, mice deficient on the phosphatase PTEN, the negative regulator of PI3K, develop breast hyperplasias and carcinomas (Stambolic et al., 2000) . In addition, overexpression of active mutants of Akt1 in the mammary gland of transgenic mice results in delayed postlactational involution and gland remodeling (Hutchinson et al., 2001; Schwertfeger et al., 2001; Ackler et al., 2002) , similar to that observed in the MMTV-Alk5 TD mice. Supporting a causal association between active Alk5 and aberrant PI3K activity and function, treatment with a small-molecule inhibitor of the Alk5 kinase inhibited PI3K and P-Akt and survival in Tg-expressing PMECs (Figure 9 ). Therefore, the data herein show for the first time in vivo and in nontumor cells that TGFb can signal to PI3K and inhibit apoptosis. In addition to a cell-autonomous, PI3K-dependent effect on cell survival, it is possible that the excess of periductal stroma (Figures 3-5 ) also plays a prosurvival role in mammary epithelium in vivo (Bhowmick et al., 2004) . This possibility will require further investigation.
In MMTV/Alk5 TD mice, the low levels of Smad2/3 and the enhanced PI3K activity may have cooperated to negate the antiproliferative effect of TGFb. However, ductal extension during gland formation was still dampened (Figure 1a ) and the mice exhibited a transient reduction in mammary secretory epithelium during pregnancy (Figure 4a-c) . Interestingly, the weight of the 3-week-old nursing pups from transgenic mothers was lower than pups from control mice, suggesting the presence of a lactational defect, consistent with, but more subtle than, that reported in WAP-TGFb1 transgenics (Jhappan et al., 1993; Boulanger et al., 2005) . reported a marked lactational deficiency in transgenic mice expressing another 'gain-of-function' mutant of Alk5 under MMTV promoter regulation. In addition to T204D, this mutant contained two missense mutations, L193A and P194A, which prevent binding of the Alk5 inhibitor FKBP12 (Charng et al., 1996) . It is possible that this mutant kinase was more potent than the Alk5 T204D mutant used in our studies, resulting in a more severe antimitogenic and proapoptotic effect, thus leading to lactational deficiency.
Finally, to determine if aberrant TGFb signaling modulated oncogene-induced tumor progression, we crossbred MMTV-Alk5 TD with MMTV-Neu mice. Mice expressing c-Neu in mammary epithelium develop mammary hyperplasias and carcinomas with a median latency of 6 months; approximately 60% of tumorbearing transgenic mice develop lung metastases (Guy et al., 1992) . Median tumor latency, number of tumors per mouse, and the calculated cumulative tumor volume were not different in MMTV-Alk5 TD Â Neu bigenics compared to MMTV-Neu mice. The tumor latency observed is not concordant with previous work demonstrating that the median time to tumor formation induced by activated forms of Neu that are selectively coupled to Grb2 or Shc signaling pathways is delayed by the coexpression of activated Alk5 containing T204D, L193A, and P194A substitutions . This difference may reflect that, in this paper, we used WT Neu, which contains all five autophosphorylation sites of the receptor. However, the number of lung metastases was greater and the timing at which they became clinically apparent was much shorter in bigenic compared to mice bearing Neu-expressing mammary tumors. The data presented here follow two recent reports: Overexpression of active TGFb1 S223/225 or the Alk5 T204D/L193A/P194A mutant under the control of the MMTV promoter in transgenic mice also expressing c-Neu or mutant Neu in mammary epithelium, respectively, accelerates lung metastases from oncogeneinduced breast carcinomas (Muraoka et al., 2003; . Therefore, our results suggest that, although the MMTV-Alk5 T204D mice did not develop mammary tumors after long followup, the mutant Alk5 kinase provides a 'gain-of-function' effect that synergizes with oncogene-induced transformation.
A dogma in this field has been that, in normal cells, the cytostatic effects of TGFb are dominant over mitogenic signals, whereas, in established cancer cells, the antiapoptotic and mitogenic action of oncogenes can subvert the growth-inhibitory action of TGFb. The implications from the data presented in this report deviate from this dogma. The phenotypic changes exhibited by the Alk5 TD -expressing PMECs, that is, increased survival and PI3K/Akt signaling and the lack of response to TGFb-induced growth inhibition, taken together, suggest a transformed phenotype. These changes occurred in cells harvested from histologically normal mammary glands containing dysregulated TGFb receptor signaling. These results suggest that, in certain contexts, that is, when low Smad2/3 and/or high PI3K/Akt signaling are present, the tumor-'promoting' effects of TGFb may also operate in epithelial cells before evidence of histological or cytological transformation is present. Based on these data, this possibility needs to be tested prospectively in human tissues.
Materials and methods
Generation and analysis of transgenic mice MMTV-TGFb1 S223/225 founders in an FVB strain background were provided by Harold Moses (Vanderbilt University). The 1.02 kb constitutively active human Alk5 T204D cDNA fragment including the carboxy-terminal HA tag was subcloned into the pBS-MMTVpA-GSK vector (D'Cruz et al., 2001 ) (provided by Lewis Chodosh, University of Pennsylvania). The linearized Tg was injected into one-cell-stage FVB mouse embryos, which were transplanted into pseudo-pregnant females. All resulting pups were screened for the presence of the Tg using primer pairs P1 and P2 (from the MMTV sequence), or P3 and P4 (from human Alk5). P1: 5 0 -CCCAAGGCTTAAGTAAGTTT TTGG-3 0 ; P2: 5 0 -GGGCATAAGCACAGATAAAACACT-3 0 ; P3: 5 0 -TTAAGATATTCTCCTCTAGAGAAGA-3 0 ; P4: 5 0 -AATCTCTATGAGCAATGGCTGGCTT-3 0 . Three independently derived transgenic founders were identified, two of which transmitted the Tg to their offspring. All subsequent studies were performed in age-matched females of the F1 or F2 generation. For studies of timed pregnancies, mating pairs were established and mice were monitored daily for vaginal plugs, the presence of which would indicate 0.5 d.p.c. Mammary glands were harvested at 16.5 d.p.c. For studies with lactating mammary glands, these were harvested 10 days post-partum (lactation day 10). For mammary involution studies, pups were withdrawn from nursing mothers on day 10 and gland involution assessed on 1, 3, 5, 7, and 21 d.p.f.w. In some cases, FVB MMTV-Neu mice (Jackson Laboratories, Bar Harbor, ME, USA) were crossed with MMTV-Alk5 TD mice to generate MMTV-Neu Â Alk5 TD bigenic mice, from which PMECs were harvested as described below. Mice were genotyped by polymerase chain reaction analysis of genomic DNA as described previously (Muraoka et al., 2003) . Only age-matched virgin female mice were analysed. Mice were monitored weekly by palpation to determine the presence of mammary tumors.
Histological analysis, TUNEL, and immunofluorescence Mammary glands were harvested and immediately fixed in 10% formalin (VWR Scientific). Hematoxylin-stained whole mounts of #4 (right inguinal) mammary glands were prepared as described previously (Muraoka et al., 2001) . Paraffinembedded mammary glands were sectioned (5 mm), rehydrated, and stained with Mayer's hematoxylin and eosin B-phloxine or with Masson's trichrome stain (all from Sigma, St Louis, MO, USA). Proliferation was determined by IHC using a PCNA antibody (Neomarkers, Freemont, CA, USA) as described (Muraoka et al., 2003) . Detection of apoptosis by TUNEL analysis was performed using the Apoptag Detection Kit (Serologicals Corp., Norcross, GA, USA) according to the manufacturer's instructions. Immunofluorescence for Smad2 and active TGFb1 was performed using fresh frozen tissue cryosections as described previously (Ehrhart et al., 1997) using the following antibodies: active TGFb1 (cat # AF-101-NA, lot FS08, R&D Systems, Minneapolis, MN, USA), Smad2/3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and secondary antibodies labeled with Alexa 488 or 594 fluorochromes (Molecular Probes, Eugene, OR, USA). Images were captured using a scientific-grade 12-bit charge-coupled device (KAF-1400, 1317 Â 1035 6.8-mm 2 pixels) digital camera (Xillix, Vancouver, Canada). Internal standardization was achieved by comparing only images stained with the same antibodies in the same experiment, captured with identical parameters, and scaled and displayed identically.
Western and Northern analyses
Mammary glands, tumors, or cell cultures were harvested and homogenized as described previously (Muraoka et al., 2003) . Total protein (20 mg) was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Western analyses were performed using the following antibodies: Alk5 (V-22), E-cadherin (H-108), integrin b1 (M-106), pan-cytokeratin (H-240), a-actinin (H-300), Smad4 (B-8), Smad7 (H79), c-myc (N-262), and HA (Santa Cruz Biotechnology, Santa Cruz, CA, USA); total and P-MAPK (Promega, Madison, WI, USA); total and S473 P-Akt and P-Smad2 (Upstate Biotechnology, Lake Placid, NY, USA); Smad2/3 (BD Biosciences Pharmingen, San Diego, CA, USA); SMA and Smad3 polyclonal (Zymed, Inc., San Francisco, CA, USA); p21 (ab-2, Oncogene Sciences). Immunoprecipitations were performed as described previously (Muraoka et al., 2001) . Total RNA was harvested from mammary glands using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's directions. Northern analysis using total RNA (20 mg) was performed as described (Muraoka et al., 2002b) .
Isolation, culture, and adenoviral transduction of PMECs Mammary glands were digested at 371C for 4 h in 3 mg/ml collagenase A (Sigma) in PBS (pH 7.4). The cell suspension was plated on dishes coated with Growth Factor-Reduced Matrigel (BD Biosciences Pharmingen) in PMEC media (Dulbecco's modified Eagle's medium : F12 (50 : 50; GibcoBRL), 10% FCS and 50 ng/ml insulin (Clonetics)) and cultured at 371C in 5% CO 2 . Human recombinant TGFb1 was from R&D Systems. PS-341 was provided by Julian Adams (Millenium Pharmaceuticals, Cambridge, MA, USA). The adenoviral constructs encoding FLAG-tagged Smad2 and Smad4 were provided by Kohei Miyazono (Japanese Foundation for Cancer Research, Tokyo). Stocks of recombinant adenoviruses were generated in 293T cells and titered using the Takara assay (Takara Biomedicals, Tokyo, Japan). Cells were then infected with these or with a control b-galactosidase adenovirus at an equivalent multiplicity of infection (moi) as described previously (Dumont et al., 2003) .
Apoptosis assay
Cells (5 Â 10 5 /well) were seeded in 6-well plates in triplicate in serum-containing medium. The following day, the medium was changed to serum-free medium containing kinase inhibitors. After 24 h, both floating and adherent cells were collected. Pooled cells were washed with PBS and then subjected to TUNEL analysis with the use of an Apo-BrdU assay kit (Phoenix Flow Systems, San Diego, CA, USA) according to the manufacturer's protocol. TUNEL þ cells were quantitated in a FACS/Calibur Flow Cytometer (BD Biosciences, Mansfield, MA, USA).
Affinity labeling of TGFb receptors
To determine the presence of TGFb receptors, PMECs were affinity-labeled with 100 pM 125 I-TGFb1 (specific activity, 3925 Ci/mmol; NEN Life Science Products, Inc., Boston, MA, USA) as described (Dumont et al., 2003) . All samples were fractionated using 3-12% gradient SDS-PAGE, followed by autoradiography.
TGFb transcriptional reporter assays PMECs (0.5 Â 10 6 per well in six well plates) were transfected with 2 mg pCAGA-Lux. After 24 h, cells were treated for 24 h with 2 ng/ml TGFb1 with or 1 mM PS-341 or both. Firefly and Renilla reniformis luciferase activities were determined by using the Promega dual-luciferase assay system. The data were normalized utilizing the ratio of firefly to R. reniformis luciferase as described previously (Dumont et al., 2003) .
PI3K activity assay PI3K activity was measured as described previously (Carpenter et al., 1997) . In brief, cells were lysed with 1% NP40 in buffer A (137 mM NaCl, 20 mM Tris-HCl, pH 7.4, 1 mM CaCl 2 , 1 mM MgCl 2 , and 0.1 mM Na orthovanadate) and a protease inhibitor cocktail (Roche). Lysates were precipitated with a p85 antibody (Upstate Biotechnology) and protein A sepharose 4B (Sigma). After washes, the immunoprecipitates (IPs) were resuspended in 80 ml of assay buffer (20 mM Hepes, 150 mM NaCl, 0.1 mM EDTA) containing 10 ml of crude brain phosphoinositides (PI, 2 mg/ml; Sigma) and 10 ml of substrate (500 mM cold ATP with 10 mCi/1 ml of [g- Hepes, pH 7.5, and 50 mM MgCl 2 ). Following gentle agitation for 10 min at room temperature, the reaction was terminated by the addition of 100 ml of 1N HCl and 200 ml of chloroform : methanol (1 : 1). The radiolabeled lipids were extracted, concentrated, and separated by TLC using silica gel plates pretreated with 1% w/v K oxalate in a solvent system of n-propanol : 2 M acetic acid (65 : 35 v/v). Incorporation of 32 P into PI was detected by autoradiography.
